October 14, 2025

Amivantamab Plus Lazertinib vs Osimertinib in EGFR-Mutated NSCLC: Overall Survival in MARIPOSA

As reported in The New England Journal of Medicine by Yang et al, the final overall survival analysis from the phase III MARIPOSA trial has shown significant benefit with amivantamab plus lazertinib v...

The ASCO Post

October 08, 2025

Risk vs. Benefit: Clinical Trial Aims to Identify Patients with Early-Stage NSCLC Who May Not Need Immunotherapy After Surgery

Many patients with early-stage non-small cell lung cancer (NSCLC) are treated post-surgery with the monoclonal antibody durvalumab (brand name Imfinzi) — an FDA-approved regimen.

Roswell Park Comprehensive Cancer Center

September 30, 2025

Single Dose of Radiation as Effective as 5-Week Course for Lung Cancer: Roswell Park Shares Results at ASTRO

Dr. Mark Farrugia describes new approach to post-operative radiation therapy for non-small cell lung cancer

Roswell Park Comprehensive Cancer Center

September 22, 2025

CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

“Maintaining quality of life during and after treatment is vital to long-term success, and these results show that perioperative nivolumab supports both survival and patient well-being,” said experts ...

The ASCO Post

February 17, 2023

Study Finds Neoadjuvant Nivolumab Led to Improved 5-Year Survival Outcomes in Patients With Resectable NSCLC

The results from a 5-year follow-up analysis of a small clinical trial of patients with stage I to IIIA non­–small cell lung cancer (NSCLC) who were treated with nivolumab for 4 weeks before surgery s...

The ASCO Post

August 09, 2023

Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial

As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit wit...

The ASCO Post

September 21, 2023

NeoCOAST: Durvalumab Monotherapy vs Combined With Other Immunotherapies for Early-Stage NSCLC

An anti–PD-L1 monoclonal antibody in combination with other immuno-oncology agents may outperform treatment with the agent on its own in the neoadjuvant setting for patients with early-stage non–small...

The ASCO Post

December 11, 2023

Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC

Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with adva...

The ASCO Post

January 13, 2025

Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality

Recent statistics showing reductions in lung cancer–related mortality may not address trends linked to tobacco use, air pollution, and asbestos exposure.

The ASCO Post